Priority Date: 07.08.12 (US 201261680473P)

PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR

  • Application ID: EP13748243
  • Status: EXAMINATION IN PROGRESS

Applicant

Technology company logo small
Technology Company

Attorneys

no operation time available
1 office
Technology Company
Employment test 51 - 200 employees
Company dna d young and co llp
operating since 1891
Headquarter in London and 2 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Specialization

This patent has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) is specialized in A61. Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 07.08.2012 - Priority Date (US 201261680473P)
  • 13.02.2014 - Publication A1 (WO2014025688)
  • 17.06.2015 - Publication A1 (EP2882440)